Physiologically-based Pharmacokinetic Models for Everolimus and Sorafenib in Mice Blog Post
Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved as an immunosuppressant and for second-line therapy of hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). Sorafenib is a multikinase…